ASCO 2020: Subtypes of kidney cancer differ in sites of metastases

A paper presented during the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program last weekend showed that histologic subtypes of metastatic renal cell carcinoma (RCC) differ in the location of their metastases. For example, lung, adrenal, brain, and pancreatic metastases occur more frequently with clear cell RCC than with papillary RCC or chromophobe […]

read more

Diagnostic biomarkers for rare subtype of kidney cancer

There are more than 10 different subtypes of renal cell carcinoma (RCC), each with important genetic differences that determine how aggressive they are or their response to treatment. Clear cell RCC is the most common subtype, accounting for 75-80% of cases. A team of scientists at the University of Michigan, USA, have discovered the gene […]

read more

Atezolizumab and bevacizumab for non-clear cell renal cell carcinoma

In this video interview from Practice Update, Dr Brad McGregor from Dana-Faber Cancer Institute in Boston, USA, talks about the results from a phase 2 trial with the combination of atezolizumab plus bevacizumab in patients with metastatic non-clear cell renal cell carcinoma (RCC). The study enrolled 60 patients, 42 of which had non-clear cell RCC […]

read more

Nivolumab for the treatment of metastatic non-clear cell renal cell carcinoma

Nivolumab alone and in combination with ipilimumab is used for the treatment of patients with metastatic renal cell carcinoma (RCC) in the second- and first-line, respectively. However, since patients with non-clear cell RCC are excluded from clinical trials, there is limited data on the effectiveness of nivolumab for the treatment of these patients. In a […]

read more

ASCO 2019: First-line pembrolizumab for advanced kidney cancer

Two presentations on the results of the KEYNOTE-427 clinical trial were given at the American Society of Clinical Oncology (ASCO) 2019 annual meeting in Chicago this week. KEYNOTE-427 is an open-label, multicentre, global phase 2 study evaluating the efficacy and safety of pembrolizumab as a first-line treatment for patients with advanced or metastatic renal cell […]

read more

Clinical course and treatment outcomes of sarcomatoid chromophobe RCC

Chromophobe renal cell carcinoma (RCC) is a rare subtype of RCC and accounts for about 5% of all RCC cases. A recent retrospective study, published in the journal Clinical Genitourinary Cancer, looked at the clinical outcomes and genomic features of 109 patients with metastatic chromophobe RCC, of which 29 had sarcomatoid features. Sarcomatoid carcinoma is […]

read more

Clinical characteristics and genomic alterations associated with outcome in chromophobe RCC

A recent study by researchers in New York, USA, and published in Clinical Genitourinary Cancer identified gene alterations and clinical characteristics that could help predict outcome in patients with a rare form of renal cell carcinoma (RCC) called chromophobe RCC. These gene alterations and clinical characteristics could also help identify potential targeted therapy options in […]

read more

Potential urine biomarkers for small renal masses

A recent study, published in the International Journal of Urology, has identified two potential biomarkers for the presence of malignant small renal masses in the urine. The study investigated aquaporin 1 and perilipin 2 to determine if these biomarkers were predictive of malignancy. During the study with 57 patients, the presence of aquaporin 1 and […]

read more

Obesity linked to the development of certain kidney cancer subtypes

Recent research has suggested that obesity is associated with the development of clear cell and possibly chromophobe renal cell carcinoma (RCC), but not papillary RCC. Read more in Renal & Urology News here

read more

Immunotherapy for non-clear cell kidney cancer

The following interview with Dr Eric Jonasch, medical oncologist from MD Anderson Cancer Centre in Texas, USA, discusses various clinical trials of immunotherapy for the treatment of rare subtypes of kidney cancer, such as papillary and chromophobe renal cell carcinoma (RCC). Dr Jonasch was interviewed at the 2018 American Society of Clinical Oncology (ASCO) annual […]

read more
Showing 1 to 10 of 12 results
  TOP